SEARCH

SEARCH BY CITATION

References

  • Ahlke, E., Nowak-Gottl, U., Schulze-Westhoff, P., Werber, G., Borste, H., Wurthwein, G., Jurgens, H. & Boos, J. (1997) Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia. British Journal of Haematology, 96, 675681.
  • Albertsen, B.K., Jakobsen, P., Schroder, H., Schmiegelow, K. & Carlsen, N.T. (2001) Pharmacokinetics of Erwinia asparaginase after intravenous and intramuscular administration. Cancer Chemotherapy and Pharmacology, 48, 7782.
  • Albrecht, J., Sidoryk-Wegrzynowicz, M., Zielinska, M. & Aschner, M. (2010) Roles of glutamine in neurotransmission. Neuron Glia Biology, 6, 263276.
  • Appel, I.M., Pinheiro, J.P., den Boer, M.L., Lanvers, C., Reniers, N.C., Boos, J. & Pieters, R. (2003) Lack of asparagine depletion in the cerebrospinal fluid after one intravenous dose of PEG-asparaginase: a window study at initial diagnosis of childhood ALL. Leukemia, 17, 22542256.
  • Asselin, B.L. (2012) The right dose for the right patient. Blood, 119, 16171618.
  • Asselin, B.L., Ryan, D., Frantz, C.N., Bernal, S.D., Leavitt, P., Sallan, S.E. & Cohen, H.J. (1989) In vitro and in vivo killing of acute lymphoblastic leukemia cells by L-asparaginase. Cancer Research, 49, 43634368.
  • Asselin, B.L., Whitin, J.C., Coppola, D.J., Rupp, I.P., Sallan, S.E. & Cohen, H.J. (1993) Comparative pharmacokinetic studies of three asparaginase preparations. Journal of Clinical oncology, 11, 17801786.
  • Avramis, V.I. & Panosyan, E.H. (2005) Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future. Clinical Pharmacokinetics, 44, 367393.
  • Avramis, V.I., Sencer, S., Periclou, A.P., Sather, H., Bostrom, B.C., Cohen, L.J., Ettinger, A.G., Ettinger, L.J., Franklin, J., Gaynon, P.S., Hilden, J.M., Lange, B., Majlessipour, F., Mathew, P., Needle, M., Neglia, J., Reaman, G., Holcenberg, J.S. & Stork, L. (2002) A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood, 99, 19861994.
  • Dibenedetto, S.P., Di, C.A., Ragusa, R., Meli, C. & Lo, N.L. (1995) Levels of L-asparagine in CSF after intramuscular administration of asparaginase from Erwinia in children with acute lymphoblastic leukemia. Journal of Clinical oncology, 13, 339344.
  • Ertel, I.J., Nesbit, M.E., Hammond, D., Weiner, J. & Sather, H. (1979) Effective dose of L-asparaginase for induction of remission in previously treated children with acute lymphocytic leukemia: a report from Childrens Cancer Study Group. Cancer Research, 39, 38933896.
  • Frandsen, T.L., Heyman, M., Abrahamsson, J., Vettenranta, K., Sberg, A., Vaitkeviciene, G., Pruunsild, K., Toft, N., Birgens, H., Hallbook, H., Quist-Paulsen, P., Griskevicius, L., Helt, L., Hansen, B.V. & Schmiegelow, K. (2014) Complying with the European Clinical Trials directive while surviving the administrative pressure – An alternative approach to toxicity registration in a cancer trial. European Journal of Cancer, 50, 251259.
  • Gentili, D., Conter, V., Rizzari, C., Tschuemperlin, B., Zucchetti, M., Orlandoni, D., D'Incalci, M. & Masera, G. (1996) L-Asparagine depletion in plasma and cerebro-spinal fluid of children with acute lymphoblastic leukemia during subsequent exposures to Erwinia L-asparaginase. Annals of Oncology, 7, 725730.
  • Gerrits, G.P., Trijbels, F.J., Monnens, L.A., Gabreels, F.J., De Abreu, R.A., Theeuwes, A.G. & van Raay-Selten, B. (1989) Reference values for amino acids in cerebrospinal fluid of children determined using ion-exchange chromatography with fluorimetric detection. Clinica Chimica Acta, 182, 271280.
  • Miller, H.K. & Balis, M.E. (1969) Glutaminase activity of L-asparagine amidohydrolase. Biochemical Pharmacology, 18, 22252232.
  • Moghrabi, A., Levy, D.E., Asselin, B., Barr, R., Clavell, L., Hurwitz, C., Samson, Y., Schorin, M., Dalton, V.K., Lipshultz, S.E., Neuberg, D.S., Gelber, R.D., Cohen, H.J., Sallan, S.E. & Silverman, L.B. (2007) Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood, 109, 896904.
  • Panetta, J.C., Gajjar, A., Hijiya, N., Hak, L.J., Cheng, C., Liu, W., Pui, C.H. & Relling, M.V. (2009) Comparison of native E. coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukemia. Clinical Pharmacology & Therapeutics, 86, 651658.
  • Panosyan, E.H., Grigoryan, R.S., Avramis, I.A., Seibel, N.L., Gaynon, P.S., Siegel, S.E., Fingert, H.J. & Avramis, V.I. (2004) Deamination of glutamine is a prerequisite for optimal asparagine deamination by asparaginases in vivo (CCG-1961). Anticancer Research, 24, 11211125.
  • Pieters, R., Hunger, S.P., Boos, J., Rizzari, C., Silverman, L., Baruchel, A., Goekbuget, N., Schrappe, M. & Pui, C.H. (2011) L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer, 117, 238249.
  • Raja, R.A., Schmiegelow, K., Albertsen, B.K., Prunsild, K., Zeller, B., Vaitkeviciene, G., Abrahamsson, J., Heyman, M., Taskinen, M., Harila-Saari, A., Kanerva, J. & Frandsen, T.L. (2014) Asparaginase-associated pancreatitis in children with acute lymphoblastic leukaemia in the NOPHO ALL2008 protocol. British Journal of Haematology, 165, 126133.
  • Riccardi, R., Holcenberg, J.S., Glaubiger, D.L., Wood, J.H. & Poplack, D.G. (1981) L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans. Cancer Research, 41, 45544558.
  • Rizzari, C., Citterio, M., Zucchetti, M., Conter, V., Chiesa, R., Colombini, A., Malguzzi, S., Silvestri, D. & D'Incalci, M. (2006) A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia. Haematologica, 91, 2431.
  • Schwartz, M.K., Lash, E.D., Oettgen, H.F. & Tomato, F.A. (1970) L-asparaginase activity in plasma and other biological fluids. Cancer, 25, 244252.
  • Sirvent, N., Suciu, S., Rialland, X., Millot, F., Benoit, Y., Plantaz, D., Ferster, A., Robert, A., Lutz, P., Nelken, B., Plouvier, E., Norton, L., Bertrand, Y. & Otten, J. (2011) Prognostic significance of the initial cerebro-spinal fluid (CSF) involvement of children with acute lymphoblastic leukaemia (ALL) treated without cranial irradiation: results of European Organization for Research and Treatment of Cancer (EORTC) Children Leukemia Group study 58881. European Journal of Cancer, 47, 239247.
  • Vieira Pinheiro, J.P., Wenner, K., Escherich, G., Lanvers-Kaminsky, C., Wurthwein, G., Janka-Schaub, G. & Boos, J. (2006) Serum asparaginase activities and asparagine concentrations in the cerebrospinal fluid after a single infusion of 2,500 IU/m(2) PEG asparaginase in children with ALL treated according to protocol COALL-06-97. Pediatric Blood & Cancer, 46, 1825.
  • Woo, M.H., Hak, L.J., Storm, M.C., Gajjar, A.J., Sandlund, J.T., Harrison, P.L., Wang, B., Pui, C.H. & Relling, M.V. (1999) Cerebrospinal fluid asparagine concentrations after Escherichia coli asparaginase in children with acute lymphoblastic leukemia. Journal of Clinical oncology, 17, 15681573.